Collaboration Agreements (Tables)

6 Months Ended

Jun. 30, 2016

Collaboration Agreements [Abstract]

Schedule of Collaboration Agreements

A financial summary of certain period activity related to our collaboration agreements is presented below^1,2:

		Three-Month Periods Ended June 30,
		Research and Development Expense
		Upfront Fees	Milestones	Extension/Termination of Agreements	Amortization of Prepaid Research and Development	Equity Investments Made During Period
Agios	2016	$200.0	$—	$—	$0.2	$—
	2015	9.0	—	—	—	—
AstraZeneca	2016	—	—	—	—	—
	2015	450.0	—	—	—	—
bluebird	2016	—	—	—	2.1	—
	2015	—	—	—	0.7	—
Juno3	2016	50.0	—	—	—	—
	2015	—	—	—	—	—
Lycera	2016	—	—	—	—	—
	2015	69.5	—	—	—	10.0
Other Collaboration Arrangements	2016	34.0	10.5	—	1.5	—
	2015	41.0	8.0	—	6.6	50.0

		Six-Month Periods Ended June 30,
		Research and Development Expense
		Upfront Fees	Milestones	Extension/Termination of Agreements	Amortization of Prepaid Research and Development	Equity Investments Made During Period
Agios	2016	$200.0	$25.0	$—	$0.2	$—
	2015	9.0	—	—	—	—
AstraZeneca	2016	—	—	—	—	—
	2015	450.0	—	—	—	—
bluebird	2016	10.0	—	—	4.2	—
	2015	—	—	—	0.7	—
Juno3	2016	50.0	—	—	—	41.0
	2015	—	—	—	—	—
Lycera	2016	—	—	—	—	—
	2015	69.5	—	—	—	10.0
Other Collaboration Arrangements	2016	104.0	50.5	—	5.4	37.0
	2015	60.0	8.0	8.1	12.1	50.0

A financial summary of the period-end balances related to our collaboration agreements is presented below:

	Balances as of:	Intangible Asset Balance	Equity Investment Balance	Percentage of Outstanding Equity
Acceleron	June 30, 2016	$—	$183.9	14%
	December 31, 2015	—	224.9	14%
Agios	June 30, 2016	0.8	219.7	14%
	December 31, 2015	1.0	340.4	13%
bluebird	June 30, 2016	16.0	N/A	N/A
	December 31, 2015	20.2	N/A	N/A
Juno	June 30, 2016	—	395.0	10%
	December 31, 2015	—	401.8	9%
Lycera	June 30, 2016	3.0	10.0	8%
	December 31, 2015	3.0	10.0	8%
Other Collaboration Arrangements	June 30, 2016	42.8	256.8	N/A
	December 31, 2015	48.4	352.0	N/A

¹  Activity and balances are presented specifically for notable new collaborations and for those collaborations which we have described in detail in our 2015 Annual Report on Form 10-K if there has been new significant activity during the periods presented. Amounts related to collaborations that are not specifically presented are included in the aggregate as Other Collaboration Arrangements.

²  In addition to the expenses noted in the tables above, we may also incur expenses for collaboration agreement related activities that are managed or funded by us.

³  Our equity investment in Juno made in the first quarter of 2016 was transacted at a price per share that exceeded the market value of Juno's publicly traded common stock on the transaction closing date, resulting in an expense for the premium of $6.0 million that was recorded in the Consolidated Statements of Income as Other income (expense), net in the first quarter of 2016.